Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
Epithelial Ovarian Carcinoma
BIOLOGICAL: DCVAC/OvCa|DRUG: Standard of Care (Paclitaxel or topotecan or doxorubicin)
Overall survival (all cause mortality), 72 weeks
Progression Free Survival, Per modified RECIST, 72 weeks|Objective Response Rate, Per RECIST, 0, 8, 16, ,24, 32, 40, 48, 56, 64, 72 weeks|Biological Progression Free Interval, 0, 8, 16, 24, 32, 40, 48, 56, 64, 72 weeks|Immunological Response, 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40 weeks|Frequency of Adverse Events, 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks|Evaluation of Quality of Life via Functional Assessment of Cancer Therapy-Ovarian, 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 48, 56, 64, 72 weeks
The purpose of this study is to determine whether DCVAC/OvCa added to Standard of Care chemotherapy may result in prolongation of Overall Survival (OS).